Serologic response to human papillomavirus 16 among Australian women with high-grade cervical intraepithelial neoplasia.
This study evaluated the detection of human papillomavirus (HPV) 16 antibody in HPV 16-associated cervical intraepithelial neoplasia (CIN) in Australian women. Seroreactivity to HPV 16 L1 virus-like particles was assessed in patients with CIN 2 (n= 169) and CIN 3 (n= 229) lesions previously tested for the presence of HPV DNA. Seropositivity was significantly commoner in women with HPV 16 DNA-positive lesions (98/184) than in women with no HPV DNA in the lesion (15/47) or with HPV of types other than 16 in the lesion (43/167) (P= 0.0004). In addition, seropositivity was observed in 33% (55/169) of women with CIN 2 and 46% (106/229) of women with CIN 3, in keeping with the lower fraction of CIN 2 (57/169) than CIN 3 (127/229) biopsies positive for HPV 16 DNA. HPV 16 seropositivity is most common in women with HPV 16-associated CIN, but many patients with HPV-associated CIN 3 are seronegative, and HPV 16 seropositivity is common in women with CIN associated with other HPV types. Overall, HPV 16 serology is a poor predictor of presence of HPV 16-associated CIN 3 in patient population studied.
Tabrizi
S N
SN
Department of Microbiology and Infectious Diseases, University of Melbourne, The Royal Women's Hospital, 132 Grattan Street, Carlton, Victoria 3053, Australia.
Frazer
I H
IH
Garland
S M
SM
D000914:Antibodies, Viral / Q000097:blood*; D000956:Antigens, Viral / Q000276:immunology; D001315:Australia; D003430:Cross-Sectional Studies; D015344:DNA Probes, HPV / Q000032:analysis; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D052162:Human papillomavirus 16 / Q000276:immunology* / Q000302:isolation & purification; D052161:Human papillomavirus 18 / Q000276:immunology; D006801:Humans; D002578:Uterine Cervical Dysplasia / Q000276:immunology / Q000821:virology*
D000914:Antibodies, Viral; D000956:Antigens, Viral; D015344:DNA Probes, HPV; D004279:DNA, Viral